Edwards Lifesciences’ recent Investor Day outlined upgraded 2025 revenue growth expectations of about 9%–10% and introduced 2026 adjusted EPS guidance of US$2.80–US$2.95, alongside anticipated constant-currency sales growth of 8%–10%.

The company underscored its transcatheter aortic valve replacement franchise as a central growth engine, reinforcing confidence in long-term opportunities despite tariff headwinds, competitive pressures, and acquisition-related earnings dilution risks.

We’ll now explore how Edwards Lifesciences’ stronger 2025 outlook and 2026 guidance could influence its previously framed growth and earnings narrative.

AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

To own Edwards Lifesciences, you essentially need to believe in sustained demand for minimally invasive heart valves, especially TAVR, and in management’s ability to protect margins despite tariffs, competition, and acquisition-related dilution. The upgraded 2025 revenue outlook and new 2026 EPS guidance support the near term growth story but do not fundamentally change the biggest swing factors, which remain early TAVR indication progress and execution on cost pressures.

The most relevant update here is the refreshed 2025 guidance, with Edwards now targeting roughly 9% to 10% revenue growth and reiterating EPS of US$2.40 to US$2.50. This sits alongside the 2026 adjusted EPS range of US$2.80 to US$2.95 and 8% to 10% constant currency sales growth, framing how management plans to absorb tariff headwinds and JenaValve dilution while still leaning on TAVR as the primary growth catalyst.

But even with this stronger outlook, investors should be aware of how rising tariffs could pressure margins and earnings if...

Read the full narrative on Edwards Lifesciences (it's free!)

Edwards Lifesciences' narrative projects $7.6 billion revenue and $1.8 billion earnings by 2028. This requires 10.0% yearly revenue growth and about a $0.4 billion earnings increase from $1.4 billion today.

Uncover how Edwards Lifesciences' forecasts yield a $93.94 fair value, a 9% upside to its current price.

Two Simply Wall St Community valuations cluster between about US$83.88 and US$93.94 per share, highlighting how differently private investors can think about fair value. Against this backdrop, the upgraded 2025 and 2026 growth guidance puts a spotlight on whether Edwards can offset tariff and acquisition related EPS headwinds over time, so it makes sense to compare several viewpoints before forming your own stance.

Explore 2 other fair value estimates on Edwards Lifesciences - why the stock might be worth just $83.88!

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your Edwards Lifesciences research is our analysis highlighting 1 key reward that could impact your investment decision.

Our free Edwards Lifesciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Edwards Lifesciences' overall financial health at a glance.

Our top stock finds are flying under the radar-for now. Get in early:

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

Rare earth metals are the new gold rush. Find out which 36 stocks are leading the charge.

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include EW.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com